U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: 3220-200986	SERIAL NO.: 10/725,191
	APPLICANT(S): Borch et al.	
	FILING DATE: Dec. 1, 2003	GROUP: 1626

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
/GS/	AA	5,233,031					
/GS/	AB	6,903,081					
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
/GS/	AL	WO 93/06120	April 1, 1993	PCT			
/GS/	AM	WO 01/74827	Oct. 11, 2001	PCT			
	AN						
	AO						

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

/GS/	AR	"The Synthesis of O-Monosaccharidyl-Methoxycarbonyl-Phosphonamidaes by Arbuzov Reaction," Chen et al., Chinese Chemical Letters, vol. 6, No. 1, pp. 23-26, 1995
	AS	"Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for *In vitro* Activity and QSAR," Siddiqui, et al., J. Med. Chem. 1999, 42, 4122-4128
	AT	"Phosphoramidates as Potent Prodrugs of Anti-HIV Nucleotides: Studies in the Amino Region," McGuigan et al., Antiviral Chemistry & Chemotherapy (1996) 7(1), 31-36
	AU	"Design and Synthesis of Novel Nucleotide Prodrugs," Meyers et al., American Association for Cancer Research 2000 (Abstract Proof Page), Abstract #100710, dated December 2, 1999
	AV	"Protein Tyrosine Kinases and Cancer," Kolibaba et al., "Biochimica et Biophysica Acta 1333 (1997) F217-F248
	AW	"Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways," van der Geer et al., Annu. Rev. Cell Biol., 1994, 10:251-337
	AX	"Src Homology Region 2 Domains Direct Protein-Protein Interactions in Signal Transduction," Moran et al., Proc. Natl. Acad. Sci. USA, Vol. 87, Nov. 1990, pp. 8622-8626
	AY	"Binding of SH2 Domains of Phospholipase Cγl, GAP, and Src to Activated Growth Factor Receptors," Anderson et al., Science, Vol. 250, Nov.16,1990, 979-982
	AZ	"Oncogenes and Signal Transduction," Cantley et al., Cell, Vol. 64, January 25, 1991, 281-302

Examiner /Golam Shameem/	Date Considered 04/02/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BASED ON FORM PTO 1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: 3220-200986	SERIAL NO.: 10/725,191
	APPLICANT(S): Borch et al.	
	FILING DATE: Dec. 1, 2003	GROUP: 1626

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	BL						
	BM						
	BN						
	BO						

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

/GS/	BR	"Recognition and Specificity in Protein Tyrosine Kinase-Mediated Signalling," Songyang et al., TIBS 20, November 1995, 470-475
	BS	"Targeting Signal Transduction in the Discovery of Antiproliferative Drugs," Saltiel et al., Chemistry & Biology, 1996, Vol. 3, No. 11, 887-893
	BT	"Peptide Inhibitors of src SH3-SH2-Phosphoprotein Interactions," Gilmer et al., The Journal of Biological Chemistry, Vol. 269, No. 50, December 16, 1994, 31711-31719
	BU	"Structure-Based Design of a Novel Series of Nonpeptide Ligands That Bind to the pp60^{src} SH2 Domain," Lunney et al., J. Am. Chem. Soc. 1997, 119, 12471-12476
	BV	"Design, Synthesis, and Cocrystal Structure of a Nonpeptide SrcSH2 Domain Ligand," Plummer et al., J. Med. Chem. 1997, 40, 3719-3725
	BW	"Inhibition of SH2 Domain/Phosphoprotein Association by a Nonhydrolyzable Phosphonopeptide," Domchek et al., Biochemistry 1992, 31, 9865-9870
	BX	"Nonhydrolyzable Phosphotyrosyl Mimetics for the Preparation of Phosphatase-resistant SH2 Domain Inhibitors," Burke, Jr., et al., Biochemistry, 1994, 33, 6490-6494
	BY	L-O-(2-Malonyl)tyrosine: A New Phosphyotyrosyl Mimetic for the Preparation of Src Homology 2 Domain Inhibitory Peptides," Ye et al., J. Med. Chem. 1995, 38, 4270-7275
	BZ	"Conformationally Constrained Phosphotyrosyl Mimetics Designed as Monomeric Src Homology 2 Domain Inhibitors," Burke Jr., et al., J. Med. Chem. 1995, 38, 1386-1396

Examiner /Golam Shameem/	Date Considered 04/02/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BASED ON FORM PTO 1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: 3220-200986	SERIAL NO.: 10/725,191
	APPLICANT(S): Borch et al.	
	FILING DATE: Dec. 1, 2003	GROUP: 1626

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If appropriate
	CA						
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						
	CK						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	CL						
	CM						
	CN						
	CO						

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

/GS/	CR	"4'-O-[2-(2-Fluoromalonyl)]-L-Tyrosine: A Phosphotyrosyl Mimic for the Preparation of Signal Transduction Inhibitory Peptides," Burke Jr., et al., J. Med. Chem. 1996, 39, 1021-1027
	CS	"Phosphotyrosine-Containing Dipeptides as High-Affinity Ligands for the p56^{lck} SH2 Domain," Llinas-Brunet et al., J. Med. Chem. 1999, 42, 722-729
	CT	"Acquisition of High-Affinity, SH2-Targeted Ligands via a Spatially Focused Library," Lee et al., J. Med. Chem. 1999, 42, 784-787
	CU	"Ligands for the Tyrosine Kinase p56-^{lck} SH2 Domain: Discovery of Potent Dipeptide Derivatives with Monocharged, Nonhydrolyzable Phosphate Replacements," Beaulieu et al., J. Med. Chem. 1999, 42, 1757-1766
	CV	"Synthesis and Biological Evaluation of 5-Fluoro-2'-Deoxyuridine Phosphoramidate Analogs," Fries et al., J. Med. Chem., 1995, 38, 2672-2680
	CW	"Synthesis and Biological Activity of Novel 5-Fluoro-2'-Deoxyuridine Phosphoramidate Prodrugs," Meyers et al., J. Med. Chem., 2000, 43, 4313-4318
	CX	"Synthesis and Evaluation of Nitroheterocyclic Phosphoramidates as Hypoxia-Selective Alkylating Agents," Borch et al., J. Med. Chem., 2000, 43, 2258-2265
	CY	Gibbs et al., Current Medicinal Chemistry, Vol. 8, No. 12, October 2001, pp. 1437-1465
	CZ	Borch et al., European Journal of Cancer. Supplement, Pergamon, Oxford, GB, Vol. 2, No. 8, September 2004, p. 176

Examiner	/Golam Shameem/	Date Considered 04/02/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BASED ON FORM PTO 1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: 3220-200986	SERIAL NO.: 10/725,191
	APPLICANT(S): Borch et al.	
	FILING DATE: Dec. 1, 2003	GROUP: 1626

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
	DA						
	DB						
	DC						
	DD						
	DE						
	DF						
	DG						
	DH						
	DI						
	DJ						
	DK						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	DL						
	DM						
	DN						
	DO						

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

/GS/	DR	Weidong et al., American Chemical Society. Abstracts of Papers at the National Meeting, ACS, Washington, D.C., Vol. 228, Part 1, 26 August 2004, p. U930
	DS	
	DT	
	DU	
	DV	
	DW	
	DX	
	DY	
	DZ	

Examiner	/Golam Shameem/	Date Considered	04/02/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BASED ON FORM PTO 1449